相关实验视频

Updated: May 20, 2025

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

本佐[a]氧衍生物C34对抗可纳耐药Candida spppp的疗效

Maria Inês Pacheco¹, Joana Carvalho-Pereira², Augusto Costa-Barbosa²

¹Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus of Gualtar, 4710-057, Braga, Portugal; Centre of Chemistry (CQUM), Department of Chemistry, University of Minho, Campus of Gualtar, 4710-057, Braga, Portugal.

Microbial pathogenesis

|March 23, 2025

概括

一种新型的[a]氨酸衍生物C34显示出强烈的抗真菌活性,对抗包括耐药菌株在内的Candida物种. 封装增强了疗效,减少了毒性因素,提供了一个有前途的新抗真菌策略.

科学领域:

菌类学菌类学是指菌类学.
药用化学医学化学
药理学药理学是指药理学的学科.

背景情况:

由于抗真菌药物耐药性,Candida感染对健康构成越来越大的挑战.
[a]氨酸衍生物因其抗菌性质而受到探索.

研究的目的:

为了评估五种[a]氧衍生物对各种Candida物种的抗真菌功效.
为了研究化合物C34的潜力,其脂质体配方,以及它对毒性因素和宿主免疫反应的影响.

主要方法:

使用EUCAST协议对C. albicans,C. auris,C. glabrata,C. parapsilosis,C. krusei和C. bracarensis进行评估的抗真菌活性.
在DODAB中封装的C34化合物:MO脂质体;有效性,粘附性和丝效应进行比较.
用MTT测定评估的细胞毒性和巨介导的酵母杀死.

主要成果:

C34对所有测试的Candida物种表现出强烈的活性 (MIC3.7560μM),包括耐可纳菌株,如C. auris.
脂质体封装C34通常改善了抗真菌功效.
自由的和封装的C34都减少了Candida的粘附和丝状,并在非细胞毒性度下增强了C. albicans的巨清除.

结论:

化合物C34对各种Candida物种,包括耐药菌株,具有显著的抗真菌潜力.
脂质体配方和病毒性因子的调节以及宿主免疫力有助于其治疗前景.
C34值得进一步研究作为一种潜在的抗真菌治疗剂.

关键词:

它具有抗真菌活性,具有抗真菌活性.在Candida spp.在DODAB:MO脂质体中.弗卢可纳醇是一种子[a]氧氨酸的存在

更多相关视频

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

相关概念视频

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.